Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Int J Mol Sci. 2022 Dec 16;23(24):16038. doi: 10.3390/ijms232416038.
Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects. In human retinal tissues, EPO receptors (EPORs) are expressed in the photoreceptor cells, retinal pigment epithelium, and retinal ganglion cell layer. Studies have suggested its potential therapeutic effects in many neurodegenerative diseases, including glaucoma. In this review, we discuss the correlation between glaucoma and EPO, physiology and potential neuroprotective function of the EPO/EPOR system, and latest evidence for the treatment of glaucoma with EPO.
促红细胞生成素（EPO）是一种循环激素，通常被认为是负责红细胞生成的。除了促进红细胞生成外，EPO 还具有多能潜能，如改善认知、神经发生、抗纤维化、抗细胞凋亡、抗氧化和抗炎作用。在人视网膜组织中，促红细胞生成素受体（EPORs）在光感受器细胞、视网膜色素上皮和视网膜神经节细胞层中表达。研究表明，它在许多神经退行性疾病中具有潜在的治疗作用，包括青光眼。在这篇综述中，我们讨论了青光眼与 EPO 之间的相关性、EPO/EPOR 系统的生理学和潜在的神经保护功能，以及 EPO 治疗青光眼的最新证据。
